Advertisement
UK markets open in 4 hours 9 minutes
  • NIKKEI 225

    38,913.48
    +296.38 (+0.77%)
     
  • HANG SENG

    18,874.97
    -320.63 (-1.67%)
     
  • CRUDE OIL

    77.03
    -0.54 (-0.70%)
     
  • GOLD FUTURES

    2,371.60
    -21.30 (-0.89%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • Bitcoin GBP

    54,580.29
    -378.89 (-0.69%)
     
  • CMC Crypto 200

    1,511.08
    -15.33 (-1.00%)
     
  • NASDAQ Composite

    16,801.54
    -31.08 (-0.18%)
     
  • UK FTSE All Share

    4,560.55
    -23.85 (-0.52%)
     

Alector to Participate in Upcoming Healthcare Conferences

Alector, Inc.
Alector, Inc.

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

  • Bank of America Securities Health Care Conference (Las Vegas, Nevada)

    • Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation

  • H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York)

    • Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

ADVERTISEMENT

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com